Commercialization· September 10, 2026 · 21 min read
ChinaMedGlobal: Checking Access Assumptions in a Licensed Drug Data Room
By Ran Chen#Market Access#Coverage Access#Payer Policy
Topic
Market Access
Market access strategy, payer engagement, formulary positioning, and commercial launch planning for biopharma products.
Policy· August 8, 2026 · 14 min read
EU Joint Clinical Assessments under the HTA Regulation: 2026 market access guide
Pricing & Access· August 3, 2026 · 15 min read
EU Pharmaceutical Procurement by the Numbers (2026): What 35,000 TED Tenders Reveal
By Ran Chen#Market Access#Generic Drugs#Drug Pricing
Pricing & Access· July 31, 2026 · 22 min read
Radioligand Therapy Access Landscape: Pluvicto, Lutathera & ITM PDUFA
By Ran Chen#Market Access#FDA Approval#HCPCS Coding
Deals· July 30, 2026 · 21 min read
Biogen's $5.6B Apellis Acquisition: Syfovre & Empaveli Q2 2026 Financial Deep Dive
By Ran Chen#M&A#Commercial Strategy#Ophthalmology
Specialty· July 30, 2026 · 20 min read
Non-Stimulant ADHD Access Landscape (2026): Simtriyo NDSRI & Generic Economics
Pricing & Access· July 25, 2026 · 30 min read
NICE Appraisals by the Numbers (2026): 1,172 Appraisals, 85% Recommended
By Ran Chen#Market Access#Payer Policy#Drug Pricing
Policy· July 17, 2026 · 18 min read
Certificate-of-Need Laws in 2026: The Specialty Drug Site-of-Care Gate
Policy· July 16, 2026 · 24 min read
Companion diagnostic change control: FDA PMA supplement vs. EU IVDR
By Ran Chen#Companion Diagnostic#FDA Approval#EMA
Approvals· July 16, 2026 · 22 min read